Home / VEGFR2/KDR/Flk-1 / Human VEGFR2/KDR/Flk-1 Antibody

Human VEGFR2/KDR/Flk-1 Antibody

Catalog #: AF357
58 Citations 2 Reviews Datasheet
Catalog # Availability Size / Price Qty
AF357
AF357-SP
Detection of Human VEGFR2/KDR/Flk‑1 by Western Blot.
8 Images
Product Details
Citations (58)
FAQs
Supplemental Products
Reviews (2)
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human VEGFR2/KDR/Flk-1 Antibody Summary

Species Reactivity
Human
Specificity
Detects human VEGFR2/KDR/Flk‑1 in direct ELISAs and Western blots. In direct ELISAs, approximately 40% cross-reactivity with recombinant mouse VEGFR2 is observed and less than 10% cross-reactivity with recombinant human (rh) VEGFR1 and rhVEGFR3 is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
Mouse myeloma cell line NS0-derived recombinant human VEGFR2/KDR/Flk-1
Ala20-Glu764
Accession # AAC16450
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
See below
Immunohistochemistry
5-15 µg/mL
See below
Neutralization
Measured by its ability to neutralize VEGFR2/KDR/Flk‑1-mediated inhibition of proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND50) is typically 0.05-0.25 µg/mL in the presence of 30 ng/mL Recombinant Human VEGFR2/KDR/Flk‑1 Fc Chimera and 5 ng/mL Recombinant Human VEGF165.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of Human VEGFR2/KDR/Flk-1 antibody by Western Blot. View Larger

Detection of Human VEGFR2/KDR/Flk‑1 by Western Blot. Western blot shows lysate of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human VEGFR2/KDR/Flk-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF357) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). Specific bands were detected for VEGFR2/KDR/Flk-1 at approximately 200-250 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Immunohistochemistry VEGFR2/KDR/Flk-1 antibody in Human Placenta by Immunohistochemistry (IHC-P). View Larger

VEGFR2/KDR/Flk‑1 in Human Placenta. VEGFR2/KDR/Flk-1 was detected in immersion fixed paraffin-embedded sections of human placenta using 15 µg/mL Goat Anti-Human VEGFR2/KDR/Flk-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF357) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-AEC Cell & Tissue Staining Kit (red; Catalog # CTS009) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Immunohistochemistry VEGFR2/KDR/Flk-1 antibody in Human Kidney by Immunohistochemistry (IHC-P). View Larger

VEGFR2/KDR/Flk‑1 in Human Kidney. VEGFR2/KDR/Flk-1 was detected in immersion fixed paraffin-embedded sections of human kidney using Goat Anti-Human VEGFR2/KDR/Flk-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF357) at 10 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Neutralization VEGFR2/KDR/Flk‑1 Inhibi-tion of VEGF-dependent Cell Proliferation and Neutral-ization by Human VEGFR2/KDR/Flk‑1 Anti-body. View Larger

VEGFR2/KDR/Flk‑1 Inhibi-tion of VEGF-dependent Cell Proliferation and Neutral-ization by Human VEGFR2/KDR/Flk‑1 Anti-body. Recombi-nant Human VEGFR2/KDR/Flk-1 Fc Chi-mera (Catalog # 357-KD) inhibits Recombinant Human VEGF165(Catalog # 293-VE) induced proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Inhibition of Recombinant Human VEGF165(5 ng/mL) activity elicited by Recombinant Human VEGFR2/KDR/Flk-1 Fc Chi-mera (30 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human VEGFR2/KDR/Flk-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF357). The ND50 is typically 0.05-0.25 µg/mL.

Immunohistochemistry Detection of Human VEGFR2/KDR/Flk-1 by Immunohistochemistry View Larger

Detection of Human VEGFR2/KDR/Flk-1 by Immunohistochemistry BMP7v exerts antiangiogenic effects and sensitizes chemoresistant CSCs to standard therapy. a Azan-Mallory staining on paraffin-embedded sections of xenografts derived from the injection of CRC sphere cells and treated for 4 weeks (6–9 weeks) with PBS (vehicle) or BMP7v. Data are representative of three independent experiments using different CRC sphere cell lines (CSC#2, 7, and 18). b Percentage of necrosis evaluated on paraffin-embedded sections of xenografts treated as in a. Data are shown as mean ± SD of three independent experiments. c Immunohistochemical analysis of CD31 and VEGFR2 (red staining) on paraffin-embedded sections of xenografts generated by the injection of CRC sphere cell lines and treated with PBS (vehicle), BMP4, or BMP7v. Green arrowheads indicate microvessels expressing CD31 or VEGFR2. Images are representative of three independent experiments using cells as in a. Nuclei were revealed by hematoxylin staining (blue). The scale bar represents 20 µm. d Number of microvessels positive for CD31 (left panel) and VEGFR2 (right panel) expression, evaluated on paraffin-embedded sections of xenografts treated as in c. Data are shown as mean ± SD of cells. MVD = microvessel density. e Fold change of viable cells in 35 CR-CSC lines treated with oxaliplatin/5-FU for 24 h. Dotted line indicates the threshold between chemoresistant (red) and sensitive CR-CSCs (green). f Cell viability percentage in chemoresistant CR-CSCs (R1-R4) pretreated with BMP7 for 3 days and with oxaliplatin/5-FU (oxa/5-FU) for additional 24 h as indicated. Data are shown as mean ± SD of three different experiments performed in the indicated R-CSCs. g Colony forming efficiency of CR-CSCs treated as in f and evaluated at 21 days. Representative soft-agar analyses are reported in the lower part of the graph. Bars show the mean ± SD of seven different CRC sphere cell lines (CSC#1–3, 5, 7, 10, and 18). h Tumor size of subcutaneous growth of the indicated CR-CSCs. Mice were treated for 4 weeks (6–9 weeks) with vehicle, oxaliplatin/5-FU (oxa/5-FU) and BMP7v alone or in combination. Error bars show the mean ± SD of tumor size measured in six mice/group. Black arrowheads indicate days of treatment. i Immunohistochemical analysis of CD44v6, beta -catenin, Ki67, and CK20 (red color) in paraffin-embedded sections of CSC#7 xenografts treated as in h. Nuclei were counterstained by aqueous hematoxylin (blue color). The scale bar represents 20 µm (left panels). Percentage of CD44v6, beta -catenin, Ki67, and CK20 positive cells in paraffin-embedded sections of tumor xenografts treated with vehicle (V), BMP7v (B), oxaliplatin/5-FU (O/F), alone or in combination (B/O/F) for 72 h. Error bars are mean ± SD of positive cell counts in three serial embedded-paraffin sections of six tumor xenografts per group derived from the injection of three different CRC sphere cells (CSC#1, 2, and 7) (right panels) Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31591478), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human VEGFR2/KDR/Flk-1 by Western Blot View Larger

Detection of Human VEGFR2/KDR/Flk-1 by Western Blot Exogenous VEGF165 suppresses RASSF1A expression in normal epithelial and endothelial cells. Metastatic colon cancer cells (mCRC, (A) T84 and (B) Colo 205) were stimulated with VEGF165 as indicated before and cell metabolism was performed by MTT assay for 6 h (black dash), 24 h (green) and 48 h (pink). Immortalized benign protate ((C) RWPE1), human bronchial epithelial cells ((D) HBEpc), immortalized human breast epithelial cells ((E) MCF-10A), endothelial cells (F, EC) were stimulated with or without VEGF165 (12.5 and 25 ng/mL) for 24 h. Cell lysates were monitored by Western blot for p-VEGFR1, p-VEGFR2, RASSF1A, and GAPDH as indicated. Immunoblot was quantified by scanning densitometry and normalized against GAPDH expression for RWPE1 (G), HBEpc (H), MCF 10A (I) and EC (lower panel of (F)). Results are from three independent experiments and statistical significance was determined using one way-ANOVA followed Bonferroni test. (* p < 0.05, ** p < 0.01, *** p < 0.001). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30744076), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human VEGFR2/KDR/Flk-1 by Western Blot View Larger

Detection of Human VEGFR2/KDR/Flk-1 by Western Blot Exogenous VEGF165 suppresses RASSF1A expression in normal epithelial and endothelial cells. Metastatic colon cancer cells (mCRC, (A) T84 and (B) Colo 205) were stimulated with VEGF165 as indicated before and cell metabolism was performed by MTT assay for 6 h (black dash), 24 h (green) and 48 h (pink). Immortalized benign protate ((C) RWPE1), human bronchial epithelial cells ((D) HBEpc), immortalized human breast epithelial cells ((E) MCF-10A), endothelial cells (F, EC) were stimulated with or without VEGF165 (12.5 and 25 ng/mL) for 24 h. Cell lysates were monitored by Western blot for p-VEGFR1, p-VEGFR2, RASSF1A, and GAPDH as indicated. Immunoblot was quantified by scanning densitometry and normalized against GAPDH expression for RWPE1 (G), HBEpc (H), MCF 10A (I) and EC (lower panel of (F)). Results are from three independent experiments and statistical significance was determined using one way-ANOVA followed Bonferroni test. (* p < 0.05, ** p < 0.01, *** p < 0.001). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30744076), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human VEGFR2/KDR/Flk-1 by Western Blot View Larger

Detection of Human VEGFR2/KDR/Flk-1 by Western Blot Exogenous VEGF165 suppresses RASSF1A expression in normal epithelial and endothelial cells. Metastatic colon cancer cells (mCRC, (A) T84 and (B) Colo 205) were stimulated with VEGF165 as indicated before and cell metabolism was performed by MTT assay for 6 h (black dash), 24 h (green) and 48 h (pink). Immortalized benign protate ((C) RWPE1), human bronchial epithelial cells ((D) HBEpc), immortalized human breast epithelial cells ((E) MCF-10A), endothelial cells (F, EC) were stimulated with or without VEGF165 (12.5 and 25 ng/mL) for 24 h. Cell lysates were monitored by Western blot for p-VEGFR1, p-VEGFR2, RASSF1A, and GAPDH as indicated. Immunoblot was quantified by scanning densitometry and normalized against GAPDH expression for RWPE1 (G), HBEpc (H), MCF 10A (I) and EC (lower panel of (F)). Results are from three independent experiments and statistical significance was determined using one way-ANOVA followed Bonferroni test. (* p < 0.05, ** p < 0.01, *** p < 0.001). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30744076), licensed under a CC-BY license. Not internally tested by R&D Systems.

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR2/KDR/Flk-1

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

VEGFR2 cDNA encodes a 1356 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 745 aa residue extracellular domain, a 25 aa residue transmembrane domain and a 567 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

References
  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
Long Name
Vascular Endothelial Growth Factor Receptor 2
Entrez Gene IDs
3791 (Human); 16542 (Mouse)
Alternate Names
CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2

Product Datasheets

You must select a language.

x
Product Datasheet

Citations for Human VEGFR2/KDR/Flk-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

58 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. A predictive microfluidic model of human glioblastoma to assess trafficking of blood–brain barrier-penetrant nanoparticles
    Authors: Joelle P. Straehla, Cynthia Hajal, Hannah C. Safford, Giovanni S. Offeddu, Natalie Boehnke, Tamara G. Dacoba et al.
    Proceedings of the National Academy of Sciences
  2. KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D
    Authors: SK Jha, K Rauniyar, E Chronowska, K Mattonet, EW Maina, H Koistinen, UH Stenman, K Alitalo, M Jeltsch
    Elife, 2019-05-17;8(0):.
  3. c-Src-induced vascular malformations require localised matrix degradation at focal adhesions
    Authors: Essebier, P;Keyser, M;Yordanov, T;Hill, B;Yu, A;Noordstra, I;Yap, AS;Stehbens, SJ;Lagendijk, AK;Schimmel, L;Gordon, EJ;
    Journal of cell science
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  4. E2 ubiquitin-conjugating enzymes, UBE2D1 and UBE2D2, regulate VEGFR2 dynamics and endothelial function
    Authors: Critchley, WR;Smith, GA;Zachary, IC;Harrison, MA;Ponnambalam, S;
    Journal of cell science
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  5. Critical role of mitogen-inducible gene 6 in restraining endothelial cell permeability to maintain vascular homeostasis
    Authors: Liying Xing, Guanqun Huang, Rongyuan Chen, Lijuan Huang, Juanxi Liu, Xiangrong Ren et al.
    Journal of Cell Communication and Signaling
  6. Galectin-3 Enhances Vascular Endothelial Growth Factor-A Receptor 2 Activity in the Presence of Vascular Endothelial Growth Factor
    Authors: Issahy Cano, Zhengping Hu, Dina B. AbuSamra, Magali Saint-Geniez, Yin Shan Eric Ng, Pablo Argüeso et al.
    Frontiers in Cell and Developmental Biology
  7. The endosomal RIN2/Rab5C machinery prevents VEGFR2 degradation to control gene expression and tip cell identity during angiogenesis
    Authors: Lanette Kempers, Yuki Wakayama, Ivo van der Bijl, Charita Furumaya, Iris M. De Cuyper, Aldo Jongejan et al.
    Angiogenesis
  8. The P-type ATPase transporter ATP7A promotes angiogenesis by limiting autophagic degradation of VEGFR2
    Authors: D Ash, V Sudhahar, SW Youn, MN Okur, A Das, JP O'Bryan, M McMenamin, Y Hou, JH Kaplan, T Fukai, M Ushio-Fuka
    Nature Communications, 2021-05-25;12(1):3091.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation, Western Blot
  9. The Role of Heparan Sulfate and Neuropilin 2 in VEGFA Signaling in Human Endothelial Tip Cells and Non-Tip Cells during Angiogenesis In Vitro
    Authors: MG Dallinga, YI Habani, AWM Schimmel, GM Dallinga-T, CJF van Noorde, I Klaassen, RO Schlingema
    Cells, 2021-04-16;10(4):.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  10. Pigment Epithelium-Derived Factor (PEDF) Receptors Are Involved in Survival of Retinal Neurons
    Authors: S Bürger, J Meng, A Zwanzig, M Beck, M Pankonin, P Wiedemann, W Eichler, JD Unterlauft
    International Journal of Molecular Sciences, 2020-12-31;22(1):.
    Species: Mouse, Rat
    Sample Types: Whole Cells
    Applications: Neutralization
  11. Elements of the Endomucin Extracellular Domain Essential for VEGF-Induced VEGFR2 Activity
    Authors: Z Hu, I Cano, KL Saez-Torre, ME LeBlanc, M Saint-Geni, YS Ng, P Argüeso, PA D'Amore
    Cells, 2020-06-05;9(6):.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  12. Shear stress activates ADAM10 sheddase to regulate Notch1 via the Piezo1 force sensor in endothelial cells
    Authors: Vincenza Caolo, Marjolaine Debant, Naima Endesh, T Simon Futers, Laeticia Lichtenstein, Fiona Bartoli et al.
    eLife
  13. Atypical chemokine receptor ACKR3/CXCR7 controls postnatal vasculogenesis and arterial specification by mesenchymal stem cells via Notch signaling
    Authors: ST Wei, YC Huang, ML Hsieh, YJ Lin, WC Shyu, HC Chen, CH Hsieh
    Cell Death Dis, 2020-05-04;11(5):307.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Western Blot
  14. ATF-2 and Tpl2 regulation of endothelial cell cycle progression and apoptosis
    Authors: GW Fearnley, AM Latham, M Hollstein, AF Odell, S Ponnambala
    Cell. Signal., 2019-11-21;66(0):109481.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  15. Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant
    Authors: V Veschi, LR Mangiapane, A Nicotra, S Di Franco, E Scavo, T Apuzzo, DS Sardina, M Fiori, A Benfante, ML Colorito, G Cocorullo, F Giuliante, C Cipolla, G Pistone, MR Bongiorno, A Rizzo, CM Tate, X Wu, S Rowlinson, LF Stancato, M Todaro, R De Maria, G Stassi
    Oncogene, 2019-10-07;0(0):.
    Species: Xenograft
    Sample Types: Whole Tissue
    Applications: IHC-P
  16. Co‐existent pilocytic astrocytoma with acute B‐cell leukemia within the cerebellum
    Authors: Richard Hickman, Rebecca Leeman‐Neill, Marc Rosenblum, Richard Anderson, James Goldman
    Neuropathology
  17. Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis
    Authors: Mélissande Cossutta, Marie Darche, Gilles Carpentier, Claire Houppe, Matteo Ponzo, Fabio Raineri et al.
    Arteriosclerosis, Thrombosis, and Vascular Biology
  18. Endophilin-A2 dependent VEGFR2 endocytosis promotes sprouting angiogenesis
    Authors: G Genet, K Boyé, T Mathivet, R Ola, F Zhang, A Dubrac, J Li, N Genet, L Henrique G, L Benedetti, S Künzel, L Pibouin-Fr, JL Thomas, A Eichmann
    Nat Commun, 2019-05-28;10(1):2350.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  19. Tpl2 is required for VEGF-A-stimulated signal transduction and endothelial cell function
    Authors: Gareth W. Fearnley, Izma Abdul-Zani, Antony M. Latham, Monica C. Hollstein, John E. Ladbury, Stephen B. Wheatcroft et al.
    Biology Open
  20. Identification of Cross Talk between FoxM1 and RASSF1A as a Therapeutic Target of Colon Cancer
    Authors: Thomas G. Blanchard, Steven J. Czinn, Vivekjyoti Banerjee, Neha Sharda, Andrea C. Bafford, Fahad Mubariz et al.
    Cancers (Basel)
  21. RCAN1.4 regulates VEGFR-2 internalisation, cell polarity and migration in human microvascular endothelial cells
    Authors: Ahmad F. Alghanem, Emma L. Wilkinson, Maxine S. Emmett, Mohammad A. Aljasir, Katherine Holmes, Beverley A. Rothermel et al.
    Angiogenesis
  22. Affimer proteins are versatile and renewable affinity reagents
    Authors: C Tiede, R Bedford, SJ Heseltine, G Smith, I Wijetunga, R Ross, D AlQallaf, AP Roberts, A Balls, A Curd, RE Hughes, H Martin, SR Needham, LC Zanetti-Do, Y Sadigh, TP Peacock, AA Tang, N Gibson, H Kyle, GW Platt, N Ingram, T Taylor, LP Coletta, I Manfield, M Knowles, S Bell, F Esteves, A Maqbool, RK Prasad, M Drinkhill, RS Bon, V Patel, SA Goodchild, M Martin-Fer, RJ Owens, JE Nettleship, ME Webb, M Harrison, JD Lippiat, S Ponnambala, M Peckham, A Smith, PK Ferrigno, M Johnson, MJ McPherson, DC Tomlinson
    Elife, 2017-06-27;6(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  23. Lymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4
    Authors: LD Volk-Drape, KL Hall, AC Wilber, S Ran
    PLoS ONE, 2017-06-09;12(6):e0179257.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  24. Endoglin prevents vascular malformation by regulating flow-induced cell migration and specification through VEGFR2 signalling
    Authors: Y Jin, L Muhl, M Burmakin, Y Wang, AC Duchez, C Betsholtz, HM Arthur, L Jakobsson
    Nat. Cell Biol., 2017-05-22;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  25. Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway
    Authors: E Leung, A Xue, Y Wang, P Rougerie, V P Sharma, R Eddy et al.
    Oncogene
  26. VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling
    Authors: K Heinolaine, S Karaman, G D'Amico, T Tammela, R Sormunen, L Eklund, K Alitalo, G Zarkada
    Circ. Res, 2017-03-15;0(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  27. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells
    Authors: Matthew T Cook, Yayun Liang, Cynthia Besch-Williford, Salman M Hyder
    Breast Cancer: Targets and Therapy
  28. VEGF induces signalling and angiogenesis by directing VEGFR2 internalisation via macropinocytosis
    J Cell Sci, 2016-09-21;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  29. VEGF-A isoforms program differential VEGFR2 signal transduction, trafficking and proteolysis
    Authors: Gareth W. Fearnley, Gina A. Smith, Izma Abdul-Zani, Nadira Yuldasheva, Nadeem A. Mughal, Shervanthi Homer-Vanniasinkam et al.
    Biology Open
  30. Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness
    Authors: ELENA PAGANI, FEDERICA RUFFINI, GIAN CARLO ANTONINI Antonini Cappellini, ALESSANDRO SCOPPOLA, CRISTINA FORTES, PAOLO MARCHETTI et al.
    International Journal of Oncology
  31. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Authors: Fiorio Pla, Alessand, Brossa, Alessia, Bernardini, Michela, Genova, Tullio, Grolez, Guillaum, Villers, Arnaud, Leroy, Xavier, Prevarskaya, Natalia, Gkika, Dimitra, Bussolati, Benedett
    BMC Cancer, 2014-12-12;14(0):939.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  32. VEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions.
    Authors: Fearnley G, Odell A, Latham A, Mughal N, Bruns A, Burgoyne N, Homer-Vanniasinkam S, Zachary I, Hollstein M, Wheatcroft S, Ponnambalam S
    Mol Biol Cell, 2014-06-25;25(16):2509-21.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  33. Control of angiogenesis by galectins involves the release of platelet-derived proangiogenic factors.
    Authors: Etulain J, Negrotto S, Tribulatti M, Croci D, Carabelli J, Campetella O, Rabinovich G, Schattner M
    PLoS ONE, 2014-04-30;9(4):e96402.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  34. Sustained delivery of VEGF maintains innervation and promotes reperfusion in ischemic skeletal muscles via NGF/GDNF signaling.
    Authors: Shvartsman, Dmitry, Storrie-White, Hannah, Lee, Kangwon, Kearney, Cathal, Brudno, Yevgeny, Ho, Nhi, Cezar, Christin, McCann, Corey, Anderson, Erin, Koullias, John, Tapia, Juan Car, Vandenburgh, Herman, Lichtman, Jeff W, Mooney, David J
    Mol Ther, 2014-04-28;22(7):1243-53.
    Species: Human
    Sample Types: Whole Cells
    Applications: Functional Assay
  35. Endothelial cell adhesion to soluble vascular endothelial growth factor receptor-1 triggers a cell dynamic and angiogenic phenotype.
    Authors: Orecchia A, Mettouchi A, Uva P, Simon G, Arcelli D, Avitabile S, Ragone G, Meneguzzi G, Pfenninger K, Zambruno G, Failla C
    FASEB J, 2013-10-30;28(2):692-704.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  36. MicroRNA-24 suppression of N-deacetylase/N-sulfotransferase-1 (NDST1) reduces endothelial cell responsiveness to vascular endothelial growth factor A (VEGFA).
    Authors: Kasza Z, Fredlund Fuchs P, Tamm C, Eriksson A, O'Callaghan P, Heindryckx F, Spillmann D, Larsson E, Le Jan S, Eriksson I, Gerwins P, Kjellen L, Kreuger J
    J Biol Chem, 2013-07-24;288(36):25956-63.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  37. Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms
    Authors: FEDERICA RUFFINI, STEFANIA D’ATRI, PEDRO M. LACAL
    International Journal of Oncology
  38. KDR identifies a conserved human and murine hepatic progenitor and instructs early liver development.
    Authors: Goldman O, Han S, Sourisseau M, Dziedzic N, Hamou W, Corneo B, D'Souza S, Sato T, Kotton D, Bissig K, Kalir T, Jacobs A, Evans T, Evans M, Gouon-Evans V
    Cell Stem Cell, 2013-06-06;12(6):748-60.
    Species: Human
    Sample Types: Whole Cells, Whole Tissue
    Applications: ICC, IHC
  39. Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between alpha V beta 3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis
    Authors: Alan C. Rapraeger, Brian J. Ell, Madhuchhanda Roy, Xuehui Li, Orrianne R. Morrison, Grant M. Thomas et al.
    FEBS Journal
  40. Ex Vivo Reconstitution of Arterial Endothelium by Embryonic Stem Cell-Derived Endothelial Progenitor Cells in Baboons
    Authors: Qiang Shi, Vida Hodara, Calvin R. Simerly, Gerald P. Schatten, John L. VandeBerg
    Stem Cells and Development
  41. Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells.
    Authors: Gourlaouen, Morgane, Welti, Jonathan, Vasudev, Naveen S, Reynolds, Andrew R
    J Biol Chem, 2013-01-22;288(11):7467-80.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  42. Vascular Endothelial Growth Factor Receptor-3 Directly Interacts with Phosphatidylinositol 3-Kinase to Regulate Lymphangiogenesis
    Authors: Sanja Coso, Yiping Zeng, Kenneth Opeskin, Elizabeth D. Williams
    PLoS ONE
  43. Differential expression of Vegfr-2 and its soluble form in preeclampsia.
    Authors: Munaut C, Lorquet S, Pequeux C, Coulon C, Le Goarant J, Chantraine F, Noel A, Goffin F, Tsatsaris V, Subtil D, Foidart JM
    PLoS ONE, 2012-03-12;7(3):e33475.
    Species: Human
    Sample Types: Plasma, Whole Tissue
    Applications: IHC-P, Western Blot
  44. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling
    Authors: Tuomas Tammela, Georgia Zarkada, Harri Nurmi, Lars Jakobsson, Krista Heinolainen, Denis Tvorogov et al.
    Nature Cell Biology
  45. Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression
    Authors: F. Ruffini, C.M. Failla, A. Orecchia, M.R. Bani, A.S. Dorio, C. Fortes et al.
    British Journal of Dermatology
  46. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines
    Authors: Ling Xu, Martin Hausmann, Wolfgang Dietmaier, Silvia Kellermeier, Theresa Pesch, Manuela Stieber-Gunckel et al.
    BMC Cancer
  47. Vascular endothelial growth factor drives autocrine epithelial cell proliferation and survival in chronic rhinosinusitis with nasal polyposis.
    Authors: Lee HS, Myers A, Kim J
    Am. J. Respir. Crit. Care Med., 2009-09-17;180(11):1056-67.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  48. The Down syndrome critical region gene 1 short variant promoters direct vascular bed-specific gene expression during inflammation in mice.
    Authors: Minami T, Yano K, Miura M, Kobayashi M, Suehiro J, Reid PC, Hamakubo T, Ryeom S, Aird WC, Kodama T
    J. Clin. Invest., 2009-07-13;119(8):2257-70.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  49. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential.
    Authors: Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M, Capogrossi MC, Failla CM, Napolitano M, Odorisio T
    Am. J. Pathol., 2006-10-01;169(4):1167-82.
    Species: Human
    Sample Types: Cell Lysates, Whole Cells
    Applications: Neutralization, Western Blot
  50. Enhancement of angiogenic effectors through hypoxia-inducible factor in preterm primate lung in vivo.
    Authors: Asikainen TM, Waleh NS, Schneider BK, Clyman RI, White CW
    Am. J. Physiol. Lung Cell Mol. Physiol., 2006-05-05;291(4):L588-95.
    Species: Primate - Papio anubis (Olive Baboon)
    Sample Types: Tissue Homogenates
    Applications: Western Blot
  51. Activation of hypoxia-inducible factors in hyperoxia through prolyl 4-hydroxylase blockade in cells and explants of primate lung.
    Authors: Asikainen TM, Schneider BK, Waleh NS, Clyman RI, Ho WB, Flippin LA, Gunzler V, White CW
    Proc. Natl. Acad. Sci. U.S.A., 2005-07-11;102(29):10212-7.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC, Neutralization
  52. PEDF derived from glial Muller cells: a possible regulator of retinal angiogenesis.
    Authors: Eichler W, Yafai Y, Keller T, Wiedemann P, Reichenbach A
    Exp. Cell Res., 2004-09-10;299(1):68-78.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  53. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.
    Authors: Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP
    Invest. Ophthalmol. Vis. Sci., 2004-02-01;45(2):368-74.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  54. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops.
    Authors: Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS
    Int. J. Cancer, 2003-05-01;104(5):603-10.
    Species: Human
    Sample Types: Cell Lysates, Whole Cells
    Applications: ICC, Western Blot
  55. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.
    Authors: Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori PP, Sammarelli G, Gazzola GC, Almici C, Caramatti C, Mangoni L, Rizzoli V
    Blood, 2003-03-20;102(2):638-45.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  56. Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects.
    Authors: Okruzhnov Y, Nicholas J
    J. Virol., 2001-11-01;75(22):10933-40.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  57. Induced hepatic stem cells are suitable for human hepatocyte production
    Authors: Yoshiki Nakashima, Chika Miyagi-Shiohira, Issei Saitoh, Masami Watanabe, Masayuki Matsushita, Masayoshi Tsukahara et al.
    iScience
  58. Perivascular Neuropilin-1 expression is an independent marker of improved survival in renal cell carcinoma
    Authors: Abdallah MG, Buchanan-Vega JA, Lee KJ, et al.
    J Pathol.

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human VEGFR2/KDR/Flk-1 Antibody

Average Rating: 3.5 (Based on 2 Reviews)

5 Star
0%
4 Star
50%
3 Star
50%
2 Star
0%
1 Star
0%

Have you used Human VEGFR2/KDR/Flk-1 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human VEGFR2/KDR/Flk-1 Antibody
By Karina Kinghorn on 08/04/2021
Application: WB Sample Tested: HUVEC human umbilical vein endothelial cells Species: Human
Western Blot Human VEGFR2/KDR/Flk-1 Antibody AF357
Human VEGFR2/KDR/Flk-1 Antibody
By Karina Kinghorn on 07/16/2021
Application: Immunocytochemistry/Immunofluorescence Sample Tested: HUVEC human umbilical vein endothelial cells Species: Human
Immunocytochemistry/Immunofluorescence Human VEGFR2/KDR/Flk-1 Antibody AF357